表紙
市場調查報告書
商品編碼
1019847

CRO(合同研究組織)服務的全球市場(~2026):類型(早期開發/臨床/實驗室)/治療領域(腫瘤/傳染病)/分子類型(疫苗/CGT)/最終用戶(限制/生物生物製藥) / 研究機構) / 按地區

Contract Research Organization (CROs) Services Market by Type (Early phase, Clinical, Laboratory), Therapeutic Area (Oncology, Infectious Disease), Molecule Type (Vaccine, CGT), End User (Pharma, Biopharma, Research Institute) - Global Forecast to 2026

出版日期: | 出版商: MarketsandMarkets | 英文 374 Pages | 訂單完成後即時交付

價格
  • 全貌
  • 簡介
  • 目錄
簡介

CRO(Contract Research Organization)服務市場規模在預測期內將保持10.7%的複合年增長率,從2021年的532億美元增長到2026年的865億美元。預計將增長.

臨床試驗數量的增加、罕見病患病率的增加以及自主研發藥物的高成本等因素正在推動市場的增長。

按類型劃分,臨床研究服務行業在 2020 年的份額最大。慢性病患病率增加和對新藥需求增加等因素正在推動該行業的增長。按地區劃分,亞太地區預計在預測期內將以最高的複合年增長率增長。政府支持和新製造設施的建設等因素正在推動該地區的增長。

本報告探討了全球合同研究組織 (CRO) 服務市場的市場定義和概述、價值鏈、新型冠狀病毒感染 (COVID-19) 和其他市場影響因素。分析、法律和監管環境、技術分析、案例研究,市場規模趨勢/預測,按類型/治療領域/分子類型/最終用戶/地區/主要國家等細分,競爭環境,主要公司簡介等。總結。

第 1 章介紹

第二章調查方法

第 3 章執行摘要

第 4 章重要考慮事項

第 5 章市場概覽

  • 市場動態
    • 促進因素
    • 市場機會
    • 挑戰
    • 趨勢
  • 範圍/場景
  • COVID-19 的影響
  • 影響客戶業務的趨勢
  • 價格分析
  • 價值鏈分析
  • 生態系統分析
  • 技術分析
  • 案例研究
  • 監管分析
  • 波特五力分析

第 6 章市場分析/預測:按類型

  • 臨床研究服務
    • 第三階段
    • 第二階段
    • 第一階段
    • 第四階段
  • 初始開發服務
    • 化學/製造/管理服務
    • 臨床前服務
    • 藥代動力學/藥效學服務
    • 毒性測試服務
    • 其他臨床前服務
    • 發現研究
  • 實驗室服務
    • 分析測試服務
    • 物理特性
    • 原材料測試
    • 批量發佈測試
    • 穩定性測試
    • 其他分析測試
    • 生物分析檢測服務
  • 諮詢服務
  • 數據管理服務

第 7 章市場分析/預測:按治療區域

  • 腫瘤
  • 傳染病
  • 神經
  • 心血管系統
  • 代謝紊亂/內分泌學
  • 免疫紊亂
  • 呼吸系統疾病
  • 精神
  • 皮膚科
  • 眼科
  • 胃腸道疾病
  • 泌尿科/女性健康
  • 其他

第 8 章市場分析/預測:按分子類型

  • 疫苗
  • 細胞/基因療法
  • 其他

第 9 章市場分析/預測:按最終用戶

  • 製藥公司/生物製藥公司
  • 醫療器械公司
  • 學術機構

第 10 章市場分析/預測:按地區/主要國家

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第11章競爭形勢

  • 大公司的成功戰略
  • 收入分析
  • 市場份額分析
  • 企業評估象限
  • 競爭基準
  • 競爭場景/趨勢

第12章公司簡介

  • 主要公司
    • IQVIA
    • LABCORP
    • SYNEOS HEALTH INC.
    • WUXI APPTEC
    • CHARLES RIVER LABORATORIES
    • PAREXEL INTERNATIONAL
    • PRA HEALTH SCIENCES
    • PPD INC
    • ICON PLC
    • MEDPACE HOLDINGS INC
    • SGS
    • FRONTAGE HOLDINGS CORPORATION
    • PSI CRO AG
    • BIO AGILE THERAPEUTICS
    • FIRMA CLINICAL RESEARCH
    • ACCULAB LIFE SCIENCES
    • NOVOTECH HEALTH HOLDINGS
    • GENETICIST INC.
    • LINICAL AMERICAS
    • CELERION
  • 其他有力企業
    • AZELIX
    • CTSERV
    • PEPGRA
    • AXCENT ADVANCED ANALYTICS(A3)
    • DOVE QUALITY SOLUTIONS

第13章 附錄

目錄
Product Code: PH 4672

The contract research organization (CRO) services market is projected to reach USD 86.5 billion by 2026 from USD 53.2 billion in 2021, at a CAGR of 10.2% during the forecast period, owing to increasing number of clinical trials, rising prevalence of orphan & rare diseases and high cost of in-house drug development.

"By type, the clinical research services segment accounted for the largest share of the contract research organization (CRO) services market"

The contract research organization (CRO) services market by type is categorized into major early-phase services, clinical research services, laboratory services, and consulting services. Clinical research services segment dominated the market in 2020. The large share of this segment can be attributed to growing demand for newer drugs and subsequent increase in the prevalence of chronic diseases.

"Asia Pacific: The fastest-growing region in the contract research organization (CRO) services market."

The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, mainly due to implementation of favorable government policies and increasing number of newly established manufacturing facilities.

"North America: the largest share of the contract research organization (CRO) services market"

North America accounted for the largest share of the contract research organization (CRO) services market. Rapid growth in the biosimilar and biologics markets and an increase in clinical trial activity are the major factors driving the market growth.

Breakdown of primaries

The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

  • By Respondent- Supply Side- 70%, Demand Side- 30%
  • By Designation- Executives- 25%, CXOs & Directors--30%, Managers - 45%
  • By Region- North America - 40%, Europe - 25%, APAC - 20%, LATAM- 10%, MEA- 5%

The contract research organization (CRO) services market is dominated by a few globally established players such as including IQVIA (US), LabCorp (US), Charles River Laboratories (US), WuXi AppTec (China), Syneos Health (US), Parexel International (US), PPD (US), and ICON Plc (US). Other players operating in the market are Medpace Holdings (US), SGS (Switzerland), PSI CRO AG (US), Axcent Advanced Analytics (US), BIO Agile Therapeutics (US), Firma Clinical Research (US), Acculab Life Sciences (US), Azelix (US), CTserv (US), Pepgra (UK), and Dove Quality Solutions (US), Novotech Health Holding (Australia), Geneticist Inc. (US), Linical Americas (US), Frontage Holding Corporation (US), and Celerion (US).

Research Coverage:

The report segments the contract research organization (CRO) services market based on region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa),

Type (Early-Phase Services (Chemistry, Manufacturing & Control, Preclinical Services (Pharmacokinetics/Pharmacodynamics (PK/PD), Toxicology Testing, Other Preclinical Services), Discovery Studies), Clinical Research Services (Phase I, Phase II, Phase III, Phase IV), Laboratory Services (Bioanalytical Testing, Analytical Testing, Physical Characterization, Raw Material Testing, Batch Release Testing, Stability Testing, Other Analytical Testing, Consulting Services, and Data Management Services), Therapeutic Area (Oncology, Infectious Diseases, Neurology, Cardiovascular System (CVS) Disorders, Metabolic Disorders/Endocrinology, Immunological Disorders, Respiratory Disorders, Psychiatry, Dermatology, Hematology, Ophthalmology, Gastrointestinal Diseases, Genitourinary & Women's Health, and Other Therapeutic Areas), End User (Pharmaceutical & Biopharmaceutical Companies, Medical Device Companies, and Academic Institutes)

The report also provides a comprehensive review of market drivers, challenges, and opportunities in the contract research organization (CRO) services market.

Key Benefits of Buying the Report:

The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the contract research organization (CRO) services market and provides them information on key market drivers, challenges, and opportunities.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • FIGURE 1 CRO SERVICES MARKET
    • 1.3.1 YEARS CONSIDERED FOR THE STUDY
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 2 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 3 CRO SERVICES MARKET: BREAKDOWN OF PRIMARIES
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: BOTTOM-UP (SUPPLY SIDE): COLLECTIVE REVENUE OF CRO SERVICES IN THE MARKET
    • FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2020
    • FIGURE 6 AVERAGE MARKET SIZE ESTIMATION, 2020
  • 2.3 GROWTH RATE ASSUMPTIONS/GROWTH FORECAST
    • FIGURE 7 CRO SERVICES MARKET: CAGR PROJECTIONS, 2021-2026
    • FIGURE 8 CRO SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES
    • FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 10 DATA TRIANGULATION METHODOLOGY
  • 2.5 INSIGHTS FROM PRIMARIES
    • FIGURE 11 MARKET VALIDATION FROM PRIMARY EXPERTS
  • 2.6 RESEARCH ASSUMPTIONS
    • 2.6.1 COVID-19 SPECIFIC ASSUMPTIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 12 CRO SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 13 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2021 VS. 2026 (USD MILLION)
    • FIGURE 14 CRO SERVICES MARKET, BY MOLECULE TYPE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 15 CRO SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    • FIGURE 16 GEOGRAPHICAL SNAPSHOT: CRO SERVICES MARKET

4 PREMIUM INSIGHTS

  • 4.1 CRO SERVICES MARKET OVERVIEW
    • FIGURE 17 RISING INVESTMENTS IN PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH
  • 4.2 NORTH AMERICA: CRO SERVICES MARKET SHARE, BY PRODUCT & COUNTRY (2020)
    • FIGURE 18 CLINICAL RESEARCH SERVICES SEGMENT ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN CRO SERVICES MARKET IN 2020
  • 4.3 CRO SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 19 CLINICAL RESEARCH SERVICES SEGMENT TO CONTINUE TO DOMINATE MARKET IN 2026
  • 4.4 CRO SERVICES MARKET SHARE, BY END USER, 2020
    • FIGURE 20 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2020
  • 4.5 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 21 ASIA PACIFIC TO REGISTER HIGHEST GROWTH IN CRO SERVICES MARKET FROM 2021 TO 2026

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 22 CRO SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 1 CRO SERVICES MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing investment in pharmaceutical R&D
    • FIGURE 23 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012-2016
    • FIGURE 24 ACTIVE PHARMACEUTICAL PIPELINE, 2011-2021
      • 5.2.1.2 Rising number of clinical trials creates significant demand for CRO services
    • FIGURE 25 INCREASING NUMBER OF CLINICAL TRIALS REGISTERED WORLDWIDE (2000-2021)
      • 5.2.1.3 High cost of in-house drug development encourages pharma biotech companies to outsource contract R&D services
    • FIGURE 26 AVERAGE COST TO DEVELOP A PHARMACEUTICAL COMPOUND FROM DISCOVERY TO LAUNCH, 2010-2020 (USD BILLION)
      • 5.2.1.4 Rising prevalence of orphan and rare diseases creates new revenue pockets for CROs
    • 5.2.2 OPPORTUNITIES
      • 5.2.2.1 Growth in drugs and biologics market despite COVID-19 pandemic
    • FIGURE 27 TOTAL NUMBER OF NEW DRUGS (NEW CHEMICAL ENTITIES AND BIOLOGICS) APPROVED BY US FDA (2001-2020)
    • TABLE 2 LIST OF BIOLOGICS APPROVALS BY US FDA, 2020
      • 5.2.2.2 Rising demand for specialized testing services among end users
      • 5.2.2.3 Need for novel clinical trial designs for complex cell and gene therapies
    • 5.2.3 CHALLENGES
      • 5.2.3.1 Shortage of skilled professionals for clinical trials
      • 5.2.3.2 Requirement for unique analytical testing approach for innovative formation
    • 5.2.4 MARKET TRENDS
      • 5.2.4.1 Revolutionary shift in CRO services market due to growing adoption of artificial intelligence-based tools for drug discovery
      • 5.2.4.2 Increased outsourcing to emerging Asian economies
      • 5.2.4.3 CRO industry consolidation
    • TABLE 3 LIST OF ACQUISITIONS
      • 5.2.4.4 Integrated end-to-end R&D service solution
  • 5.3 RANGES/SCENARIO
    • FIGURE 28 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF CRO SERVICES MARKET
  • 5.4 IMPACT OF COVID-19 OUTBREAK ON CRO SERVICES MARKET
    • FIGURE 29 CRO SERVICES MARKET SCENARIO WITH AND WITHOUT COVID-19 IMPACT, 2019-2021
  • 5.5 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
    • FIGURE 30 REVENUE SHIFT & NEW POCKETS FOR CRO SERVICE PROVIDERS
  • 5.6 PRICING ANALYSIS
    • TABLE 4 AVERAGE SELLING PRICE OF CRO SERVICES, BY REGION (2020)
  • 5.7 VALUE CHAIN ANALYSIS
    • FIGURE 31 VALUE CHAIN ANALYSIS OF CRO SERVICES MARKET: CLINICAL RESEARCH PHASES ADD MAXIMUM VALUE
  • 5.8 ECOSYSTEM ANALYSIS
    • FIGURE 32 ECOSYSTEM ANALYSIS: CRO SERVICES MARKET
    • TABLE 5 SUPPLY CHAIN ECOSYSTEM
  • 5.9 TECHNOLOGY ANALYSIS
  • 5.10 CASE STUDY
    • 5.10.1 COVANCE FSPX DATA ANALYSIS USED TO DETERMINE ELIGIBILITY OF PATIENTS ENROLLED FOR ONCOLOGY CLINICAL TRIAL
    • 5.10.2 IQVIA PROVIDES END-TO-END CLINICAL SUPPORT TO SPONSOR
  • 5.11 REGULATORY ANALYSIS
  • 5.12 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 6 CRO SERVICES MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.12.1 THREAT OF NEW ENTRANTS
    • 5.12.2 THREAT OF SUBSTITUTES
    • 5.12.3 BARGAINING POWER OF BUYERS
    • 5.12.4 BARGAINING POWER OF SUPPLIERS
    • 5.12.5 DEGREE OF COMPETITION

6 CRO SERVICES MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 7 CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
  • 6.2 CLINICAL RESEARCH SERVICES
    • 6.2.1 GROWING NUMBER OF CLINICAL TRIALS AND PARTNERSHIPS WITH CROS PROPEL GROWTH OF SEGMENT
    • TABLE 8 NUMBER OF REGISTERED AND RECRUITING CLINICAL STUDIES AS OF JUNE 2021, BY LOCATION
    • TABLE 9 EXAMPLES OF CLINICAL RESEARCH SERVICES OFFERED BY MARKET PLAYERS
    • FIGURE 33 DRUGS IN PIPELINE, BY DEVELOPMENT PHASE, 2019 VS. 2020
    • TABLE 10 CLINICAL RESEARCH SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 11 CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 12 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 13 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 14 ASIA PACIFIC: CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.2.2 PHASE III CLINICAL RESEARCH SERVICES
      • 6.2.2.1 Rising cost of Phase III trials and high number of patients recruited in these trials increases demand for cost effective CRO services
    • TABLE 15 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE III STUDY
    • TABLE 16 PHASE III CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 17 NORTH AMERICA: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 18 EUROPE: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 19 ASIA PACIFIC: PHASE III CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.2.3 PHASE II CLINICAL RESEARCH SERVICES
      • 6.2.3.1 Long duration of Phase II studies provides growth opportunities for CROs
    • TABLE 20 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE II STUDIES
    • TABLE 21 PHASE II CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 22 NORTH AMERICA: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 23 EUROPE: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 24 ASIA PACIFIC: PHASE II CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.2.4 PHASE I CLINICAL RESEARCH SERVICES
      • 6.2.4.1 Robust pipeline of pharmaceutical companies drives segment growth
    • TABLE 25 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE I STUDIES
    • TABLE 26 PHASE I CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 27 NORTH AMERICA: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 28 EUROPE: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 29 ASIA PACIFIC: PHASE I CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.2.5 PHASE IV CLINICAL RESEARCH SERVICES
      • 6.2.5.1 Rising number of CROs providing post-marketing surveillance drives segment growth
    • TABLE 30 EXAMPLES OF DRUGS THAT HAVE COMPLETED PHASE IV CLINICAL STUDIES
    • TABLE 31 PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 32 NORTH AMERICA: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 33 EUROPE: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 34 ASIA PACIFIC: PHASE IV CLINICAL RESEARCH SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.3 EARLY-PHASE DEVELOPMENT SERVICES
    • 6.3.1 RISING NEED FOR EARLY-PHASE DEVELOPMENT STUDIES FOR BIOLOGICS AND BIOSIMILARS TO DRIVE SEGMENT GROWTH
    • FIGURE 34 DRUGS IN PIPELINE, BY THERAPEUTIC AREA (2019)
    • TABLE 35 EXAMPLES OF EARLY-PHASE DEVELOPMENT SERVICES OFFERED BY MARKET PLAYERS
    • TABLE 36 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 37 EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 38 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 39 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 40 ASIA PACIFIC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.3.2 CHEMISTRY, MANUFACTURING & CONTROL SERVICES
      • 6.3.2.1 High demand for CMC services to check quality standards of drugs
    • TABLE 41 CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 42 NORTH AMERICA: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 43 EUROPE: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 44 ASIA PACIFIC: CHEMISTRY, MANUFACTURING & CONTROL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.3.3 PRECLINICAL SERVICES
      • 6.3.3.1 Rising demand for preclinical services for PK/PD and toxicology testing propels growth of segment
    • TABLE 45 PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 46 PRECLINICAL SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 47 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 48 EUROPE: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 49 ASIA PACIFIC: PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.3.4 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES
      • 6.3.4.1 Increasing importance of studies to determine pharmacokinetic behavior of drug candidates to drive segment
    • TABLE 50 PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 51 NORTH AMERICA: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 52 EUROPE: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 53 ASIA PACIFIC: PHARMACOKINETICS/PHARMACODYNAMICS SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.3.5 TOXICOLOGY TESTING SERVICES
    • TABLE 54 TOXICOLOGY TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 55 NORTH AMERICA: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 56 EUROPE: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 57 ASIA PACIFIC: TOXICOLOGY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.3.6 OTHER PRECLINICAL SERVICES
      • 6.3.6.1 Increasing use of molecular imaging, flow cytometry, and immunohistochemistry to boost segment
    • TABLE 58 OTHER PRECLINICAL SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 59 NORTH AMERICA: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 60 EUROPE: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 61 ASIA PACIFIC: OTHER PRECLINICAL SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.3.7 DISCOVERY STUDIES
      • 6.3.7.1 Rising importance of CRO services for target identification and validation to promote segment growth
    • TABLE 62 DISCOVERY STUDIES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 63 NORTH AMERICA: DISCOVERY STUDIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 64 EUROPE: DISCOVERY STUDIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 65 ASIA PACIFIC: DISCOVERY STUDIES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.4 LABORATORY SERVICES
    • 6.4.1 INCREASING IMPORTANCE OF LAB SERVICES TO ENSURE REGULATORY COMPLIANCE TO PROPEL SEGMENT GROWTH
    • TABLE 66 EXAMPLES OF LABORATORY SERVICES OFFERED BY PROMINENT PLAYERS
    • TABLE 67 LAB SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 68 LAB SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 69 NORTH AMERICA: LAB SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 70 EUROPE: LAB SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 71 ASIA PACIFIC: LAB SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.4.2 ANALYTICAL TESTING SERVICES
      • 6.4.2.1 Increasing demand for analytical testing for all stages of drug development drive growth of segment
    • TABLE 72 ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 73 ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 74 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 75 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 76 ASIA PACIFIC: ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.4.3 PHYSICAL CHARACTERIZATION
      • 6.4.3.1 Increasing demand for physical characterization to reduce risk of product failure drives segment growth
    • TABLE 77 PHYSICAL CHARACTERIZATION SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 78 NORTH AMERICA: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 79 EUROPE: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 80 ASIA PACIFIC: PHYSICAL CHARACTERIZATION SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.4.4 RAW MATERIAL TESTING
      • 6.4.4.1 High demand for testing services to ensure quality and purity of raw materials drives growth of segment
    • TABLE 81 RAW MATERIAL TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 82 NORTH AMERICA: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 83 EUROPE: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 84 ASIA PACIFIC: RAW MATERIAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.4.5 BATCH RELEASE TESTING
      • 6.4.5.1 Comprehensive portfolio of batch-release testing services offered by CROs to propel segment growth
    • TABLE 85 BATCH RELEASE TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 86 NORTH AMERICA: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 87 EUROPE: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 88 ASIA PACIFIC: BATCH RELEASE TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.4.6 STABILITY TESTING
      • 6.4.6.1 Used to ensure long-term quality, safety, and efficacy of pharmaceutical products
    • TABLE 89 STABILITY TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 90 NORTH AMERICA: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 91 EUROPE: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 92 ASIA PACIFIC: STABILITY TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.4.7 OTHER ANALYTICAL TESTING
      • 6.4.7.1 Demand for analytical method validation, cleaning validation, and microbial testing to propel segment growth
    • TABLE 93 OTHER ANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 94 NORTH AMERICA: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 95 EUROPE: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 96 ASIA PACIFIC: OTHER ANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • 6.4.8 BIOANALYTICAL TESTING SERVICES
      • 6.4.8.1 High demand for bioanalytical testing due to growing use of macromolecules and biosimilars
    • TABLE 97 BIOANALYTICAL TESTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 98 NORTH AMERICA: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 99 EUROPE: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 100 ASIA PACIFIC: BIOANALYTICAL TESTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.5 CONSULTING SERVICES
    • 6.5.1 INCREASING ADOPTION OF CONSULTING SERVICES FOR QUALITY ASSURANCE PURPOSES PROPELS SEGMENT GROWTH
    • TABLE 101 CONSULTING SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 102 NORTH AMERICA: CONSULTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 103 EUROPE: CONSULTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 104 ASIA PACIFIC: CONSULTING SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.6 DATA MANAGEMENT SERVICES
    • 6.6.1 DATA MANAGEMENT SERVICES EXPECTED TO RECORD HIGHEST CAGR DURING FORECAST PERIOD
    • TABLE 105 EXAMPLES OF DATA MANAGEMENT SERVICES OFFERED BY PROMINENT PLAYERS
    • TABLE 106 DATA MANAGEMENT SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 107 NORTH AMERICA: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 108 EUROPE: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 109 ASIA PACIFIC: DATA MANAGEMENT SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

7 CRO SERVICES MARKET, BY THERAPEUTIC AREA

  • 7.1 INTRODUCTION
    • TABLE 110 CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
  • 7.2 ONCOLOGY
    • 7.2.1 INCREASING NUMBER OF CANCER CASES DRIVES GROWTH OF SEGMENT
    • FIGURE 35 INCIDENCE OF ALL TYPES OF CANCER CASES WORLDWIDE (2020)
    • FIGURE 36 NUMBER OF ONCOLOGY CLINICAL TRIALS STARTED GLOBALLY FROM 2010 TO 2018 (IN THOUSANDS)
    • TABLE 111 LIST OF FDA DRUGS APPROVED FOR ONCOLOGY (2020)
    • TABLE 112 CRO SERVICES MARKET FOR ONCOLOGY, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 113 NORTH AMERICA: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 114 EUROPE: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 115 ASIA PACIFIC: CRO SERVICES MARKET FOR ONCOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.3 INFECTIOUS DISEASES
    • 7.3.1 EPIDEMIC OUTBREAKS NECESSITATE INCREASING DRUG DISCOVERY ACTIVITIES
    • TABLE 116 CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 117 NORTH AMERICA: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 118 EUROPE: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 119 ASIA PACIFIC: CRO SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.4 NEUROLOGY
    • 7.4.1 INCREASING INVESTMENT IN R&D AND GRANTS FOR NEUROLOGICAL DISORDERS DRIVES MARKET
    • TABLE 120 LIST OF PIPELINE DRUGS FOR NEUROLOGICAL DISORDERS (2020)
    • TABLE 121 CRO SERVICES MARKET FOR NEUROLOGY, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 122 NORTH AMERICA: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 123 EUROPE: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 124 ASIA PACIFIC: CRO SERVICES MARKET FOR NEUROLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.5 CARDIOVASCULAR SYSTEM DISORDERS
    • 7.5.1 HIGH MORTALITY RATES DRIVING PHARMACEUTICAL COMPANIES TO DEVELOP NEW TREATMENT OPTIONS
    • TABLE 125 LIST OF PIPELINE DRUGS FOR CARDIOVASCULAR DISEASES (2020)
    • TABLE 126 CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 127 NORTH AMERICA: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 128 EUROPE: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 129 ASIA PACIFIC: CRO SERVICES MARKET FOR CARDIOVASCULAR SYSTEM DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.6 METABOLIC DISORDERS/ENDOCRINOLOGY
    • 7.6.1 INCREASING GLOBAL DIABETES POPULATION EXPECTED TO DRIVE MARKET GROWTH
    • FIGURE 37 ESTIMATED NUMBER OF INDIVIDUALS WITH DIABETES FROM 2000 TO 2045 (IN MILLIONS)
    • TABLE 130 CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 131 NORTH AMERICA: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 132 EUROPE: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 133 ASIA PACIFIC: CRO SERVICES MARKET FOR METABOLIC DISORDERS/ENDOCRINOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.7 IMMUNOLOGICAL DISORDERS
    • 7.7.1 GROWING IMMUNOLOGIAL DRUGS PIPELINE RESULTING IN INCREASE IN OUTSOURCING ACTIVITIES
    • TABLE 134 CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 135 NORTH AMERICA: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 136 EUROPE: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 137 ASIA PACIFIC: CRO SERVICES MARKET FOR IMMUNOLOGICAL DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.8 RESPIRATORY DISORDERS
    • 7.8.1 INCREASING PREVALENCE OF RESPIRATORY DISEASE TO SUPPORT GROWTH OF SEGMENT
    • TABLE 138 LIST OF PIPELINE DRUGS FOR RESPIRATORY DISEASES (2020)
    • TABLE 139 CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 140 NORTH AMERICA: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 141 EUROPE: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 142 ASIA PACIFIC: CRO SERVICES MARKET FOR RESPIRATORY DISORDERS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.9 PSYCHIATRY
    • 7.9.1 RISING INCIDENCE OF PSYCHIATRIC DISORDERS TO PROPEL MARKET GROWTH
    • TABLE 143 CRO SERVICES MARKET FOR PSYCHIATRY, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 144 NORTH AMERICA: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 145 EUROPE: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 146 ASIA PACIFIC: CRO SERVICES MARKET FOR PSYCHIATRY, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.10 DERMATOLOGY
    • 7.10.1 INCREASING PREVALENCE OF SKIN DISORDERS PROPELS SEGMENT GROWTH
    • TABLE 147 LIST OF PIPELINE DRUGS FOR SKIN DISEASES (2020)
    • TABLE 148 CRO SERVICES MARKET FOR DERMATOLOGY, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 149 NORTH AMERICA: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 150 EUROPE: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 151 ASIA PACIFIC: CRO SERVICES MARKET FOR DERMATOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.11 HEMATOLOGY
    • 7.11.1 DEVELOPMENT OF DRUGS FOR HEMATOLOGICAL DISORDERS TO DRIVE SEGMENT GROWTH
    • TABLE 152 CRO SERVICES MARKET FOR HAEMATOLOGY, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 153 NORTH AMERICA: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 154 EUROPE: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 155 ASIA PACIFIC: CRO SERVICES MARKET FOR HAEMATOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.12 OPHTHALMOLOGY
    • 7.12.1 GROWING NEED FOR OPTHALMOLOGY-RELATED CLINICAL TRIALS
    • TABLE 156 CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 157 NORTH AMERICA: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 158 EUROPE: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 159 ASIA PACIFIC: CRO SERVICES MARKET FOR OPHTHALMOLOGY, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.13 GASTROINTESTINAL DISEASES
    • 7.13.1 RISING INCIDENCE OF GASTROINTESTINAL DISEASES AND GROWING INVESTMENT IN R&D TO PROPEL MARKET
    • TABLE 160 CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 161 NORTH AMERICA: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 162 EUROPE: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 163 ASIA PACIFIC: CRO SERVICES MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.14 GENITOURINARY & WOMEN'S HEALTH
    • 7.14.1 RISING PREVALENCE OF CHRONIC DISORDERS IN WOMEN DRIVES SEGMENT GROWTH
    • TABLE 164 CRO SERVICES MARKET FOR GENITOURINARY & WOMEN'S HEALTH, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 165 NORTH AMERICA: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN'S HEALTH, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 166 EUROPE: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN'S HEALTH, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 167 ASIA PACIFIC: CRO SERVICES MARKET FOR GENITOURINARY & WOMEN'S HEALTH, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.15 OTHER THERAPEUTIC AREAS
    • 7.15.1 PROMISING DRUGS IN PIPELINE FOR RARE DISEASES TO SUPPPORT SEGMENT GROWTH
    • TABLE 168 CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 169 NORTH AMERICA: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 170 EUROPE: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 171 ASIA PACIFIC: CRO SERVICES MARKET FOR OTHER THERAPEUTIC AREAS, BY COUNTRY, 2019-2026 (USD MILLION)

8 CRO SERVICES MARKET, BY MOLECULE TYPE

  • 8.1 INTRODUCTION
    • TABLE 172 CRO SERVICES MARKET, BY MOLECULE TYPE, 2019-2026 (USD MILLION)
  • 8.2 VACCINES
    • 8.2.1 RISING FOCUS ON IMMUNIZATION FOR INFECTIOUS DISEASES FUELING MARKET GROWTH
    • TABLE 173 COVID-19 VACICNES IN PIPELINE
    • TABLE 174 CRO SERVICES MARKET FOR VACCINES, BY REGION, 2019-2026 (USD MILLION)
  • 8.3 CELL & GENE THERAPY
    • 8.3.1 INCREASING FUNDING FOR R&D SUPPORTS MARKET GROWTH
  • 8.4 OTHER MOLECULE TYPES

9 CRO SERVICES MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 175 CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 9.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 9.2.1 INCREASING R&D EXPENDITURE AND ROBUST PIPELINE TO DRIVE MARKET GROWTH
    • FIGURE 38 ANNUAL DRUG APPROVALS BY FDA'S CDER (2009-2018)
    • FIGURE 39 R&D SPENDING OF PHRMA MEMBER COMPANIES, 2011-2018
    • TABLE 176 CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 177 NORTH AMERICA: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 178 EUROPE: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 179 ASIA PACIFIC: CRO SERVICES MARKET FOR PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.3 MEDICAL DEVICE COMPANIES
    • 9.3.1 INCREASE IN R&D FOR DEVELOPMENT OF ADVANCED MEDICAL DEVICES FUELING MARKET GROWTH
    • FIGURE 40 US FDA DE NOVO MEDICAL DEVICE APPROVALS (2010-2020)
    • FIGURE 41 R&D EXPENSES OF LEADING MEDICAL DEVICE COMPANIES (IN USD MILLION), 2020
    • TABLE 180 CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 181 NORTH AMERICA: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 182 EUROPE: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 183 ASIA PACIFIC: CRO SERVICES MARKET FOR MEDICAL DEVICE COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.4 ACADEMIC INSTITUTES
    • 9.4.1 COLLABORATION WITH MARKET PLAYERS TO PROVIDE MORE FLEXIBLE AND EFFICIENT PATHWAYS FOR CLINICAL DEVELOPMENT
    • TABLE 184 CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 185 NORTH AMERICA: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 186 EUROPE: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 187 ASIA PACIFIC: CRO SERVICES MARKET FOR ACADEMIC INSTITUTES, BY COUNTRY, 2019-2026 (USD MILLION)

10 CRO SERVICES MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 188 CRO SERVICES MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 42 NORTH AMERICA: CRO SERVICES MARKET SNAPSHOT
    • TABLE 189 NORTH AMERICA: CRO SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 190 NORTH AMERICA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 191 NORTH AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 192 NORTH AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 193 NORTH AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 194 NORTH AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 195 NORTH AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 196 NORTH AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 197 NORTH AMERICA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Largest CRO services market in North America due to robust clinical trial activities
    • FIGURE 43 US CONTINUES TO DOMINATE DISTRIBUTION OF R&D COMPANIES BY REGION (2020 VS. 2019)
    • TABLE 198 US: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 199 US: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 200 US: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 201 US: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 202 US: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 203 US: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 204 US: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 205 US: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Increasing number of clinical trials to support market growth
    • TABLE 206 CANADA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 207 CANADA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 208 CANADA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 209 CANADA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 210 CANADA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 211 CANADA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 212 CANADA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 213 CANADA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.3 EUROPE
    • FIGURE 44 CLINICAL TRIALS CONDUCTED IN EUROPE SINCE 2008 (2018)
    • TABLE 214 EUROPE: CRO SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 215 EUROPE: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 216 EUROPE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 217 EUROPE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 218 EUROPE: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 219 EUROPE: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 220 EUROPE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 221 EUROPE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 222 EUROPE: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Favorable location for clinical trials due to government support and flexible labor laws
    • TABLE 223 GERMANY: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 224 GERMANY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 225 GERMANY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 226 GERMANY: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 227 GERMANY: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 228 GERMANY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 229 GERMANY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 230 GERMANY: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 Investment by pharmaceutical sponsors for drug discovery services to support market growth
    • FIGURE 45 UK: PHARMACEUTICAL R&D EXPENDITURE, 2013-2017 (USD MILLION)
    • TABLE 231 UK: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 232 UK: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 233 UK: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 234 UK: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 235 UK: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 236 UK: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 237 UK: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 238 UK: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 High number of oncology clinical trials to drive market growth
    • TABLE 239 FRANCE: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 240 FRANCE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 241 FRANCE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 242 FRANCE: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 243 FRANCE: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 244 FRANCE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 245 FRANCE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 246 FRANCE: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.4 ITALY
      • 10.3.4.1 Low drug approval time and growing number of clinical trials to drive market growth
    • TABLE 247 NUMBER OF CLINICAL TRIALS STARTED IN ITALY, BY COMPANY (JANUARY 2021)
    • TABLE 248 ITALY: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 249 ITALY: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 250 ITALY: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 251 ITALY: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 252 ITALY: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 253 ITALY: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 254 ITALY: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 255 ITALY: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.5 SPAIN
      • 10.3.5.1 Short study start-up times and rising R&D expenditure to boost market growth
    • FIGURE 46 SPAIN: PHARMACEUTICAL R&D EXPENDITURE (USD MILLION), 2011-2017
    • TABLE 256 SPAIN: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 257 SPAIN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 258 SPAIN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 259 SPAIN: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 260 SPAIN: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 261 SPAIN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 262 SPAIN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 263 SPAIN: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.6 REST OF EUROPE
    • TABLE 264 ROE: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 265 ROE: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 266 ROE: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 267 ROE: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 268 ROE: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 269 ROE: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 270 ROE: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 271 ROE: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 47 ASIA PACIFIC: CRO SERVICES MARKET SNAPSHOT
    • TABLE 272 APAC: CRO SERVICES MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 273 APAC: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 274 APAC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 275 APAC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 276 APAC: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 277 APAC: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 278 APAC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 279 APAC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 280 APAC: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 Dominates market due to robust pharmaceutical industry and presence of prominent CROs
    • TABLE 281 CHINA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 282 CHINA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 283 CHINA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 284 CHINA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 285 CHINA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 286 CHINA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 287 CHINA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 288 CHINA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Strong focus on research to drive market growth
    • TABLE 289 TOTAL NUMBER OF CLINICAL TRIALS IN JAPAN, BY THERAPEUTIC AREA, 2017 VS. 2019
    • TABLE 290 JAPAN: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 291 JAPAN: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 292 JAPAN: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 293 JAPAN: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 294 JAPAN: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 295 JAPAN: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 296 JAPAN: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 297 JAPAN: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.3 INDIA
      • 10.4.3.1 Growing pharmaceutical industry to drive market growth
    • TABLE 298 TOTAL NUMBER OF CLINICAL TRIALS IN INDIA, BY THERAPEUTIC AREA, 2017 VS. 2019
    • TABLE 299 INDIA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 300 INDIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 301 INDIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 302 INDIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 303 INDIA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 304 INDIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 305 INDIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 306 INDIA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.4 AUSTRALIA
      • 10.4.4.1 Favorable location for drug discovery due to large number of research institutes
    • TABLE 307 AUSTRALIA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 308 AUSTRALIA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 309 AUSTRALIA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 310 AUSTRALIA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 311 AUSTRALIA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 312 AUSTRALIA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 313 AUSTRALIA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 314 AUSTRALIA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.5 SOUTH KOREA
      • 10.4.5.1 Government initiatives and growing R&D activities for drug development to drive market growth
    • TABLE 315 SOUTH KOREA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 316 SOUTH KOREA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 317 SOUTH KOREA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 318 SOUTH KOREA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 319 SOUTH KOREA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 320 SOUTH KOREA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 321 SOUTH KOREA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 322 SOUTH KOREA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.6 REST OF ASIA PACIFIC
    • TABLE 323 TOTAL NUMBER OF CLINICAL TRIALS IN SINGAPORE AND MALAYSIA, BY THERAPEUTIC AREA, 2017 VS. 2019
    • TABLE 324 ROAPAC: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 325 ROAPAC: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 326 ROAPAC: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 327 ROAPAC: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 328 ROAPAC: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 329 ROAPAC: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 330 ROAPAC: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 331 ROAPAC: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 GROWING R&D EXPENDITURE IN PHARMACEUTICAL & BIOPHARMACEUTICAL SECTOR TO DRIVE MARKET GROWTH
    • TABLE 332 LATIN AMERICA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 333 LATIN AMERICA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 334 LATIN AMERICA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 335 LATIN AMERICA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 336 LATIN AMERICA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 337 LATIN AMERICA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 338 LATIN AMERICA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 339 LATIN AMERICA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 GROWING PHARMACEUTICAL INDUSTRY TO DRIVE MARKET GROWTH
    • TABLE 340 MEA: CRO SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 341 MEA: CLINICAL RESEARCH SERVICES MARKET, BY PHASE, 2019-2026 (USD MILLION)
    • TABLE 342 MEA: EARLY-PHASE DEVELOPMENT SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 343 MEA: PRECLINICAL SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 344 MEA: LABORATORY SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 345 MEA: ANALYTICAL TESTING SERVICES MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 346 MEA: CRO SERVICES MARKET, BY THERAPEUTIC AREA, 2019-2026 (USD MILLION)
    • TABLE 347 MEA: CRO SERVICES MARKET, BY END USER, 2019-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 INTRODUCTION
  • 11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
    • FIGURE 48 CRO SERVICES MARKET: STRATEGIES ADOPTED
  • 11.3 REVENUE ANALYSIS
    • FIGURE 49 REVENUE ANALYSIS FOR KEY COMPANIES OVER THE PAST THREE YEARS
  • 11.4 MARKET SHARE ANALYSIS
    • FIGURE 50 CRO SERVICES MARKET: MARKET SHARE ANALYSIS OF KEY PLAYERS (2020)
  • 11.5 COMPANY EVALUATION QUADRANT
    • FIGURE 51 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX, 2020
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE PLAYERS
    • 11.5.4 PARTICIPANTS
  • 11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
    • FIGURE 52 CRO SERVICES MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2020
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
  • 11.7 COMPETITIVE BENCHMARKING
    • 11.7.1 COMPANY SERVICE FOOTPRINT (20 COMPANIES)
    • FIGURE 53 SERVICE FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
    • 11.7.2 COMPANY INDUSTRY FOOTPRINT (20 COMPANIES)
    • TABLE 348 INDUSTRY FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
    • 11.7.3 COMPANY SERVICE OFFERING FOOTPRINT (20 COMPANIES)
    • TABLE 349 SERVICE OFFERING FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
    • 11.7.4 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
    • TABLE 350 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN CRO SERVICES MARKET
  • 11.8 COMPETITIVE SCENARIO AND TRENDS
    • 11.8.1 SERVICES LAUNCHES
    • TABLE 351 CRO SERVICES MARKET: SERVICE LAUNCHES, JANUARY 2017-NOVEMBER 2020
    • 11.8.2 DEALS
    • TABLE 352 CRO SERVICES MARKET: DEALS, JANUARY 2017-NOVEMBER 2020
    • 11.8.3 OTHER DEVELOPMENTS
    • TABLE 353 CRO SERVICES MARKET: EXPANSION, JANUARY 2017-NOVEMBER 2020

12 COMPANY PROFILES

  • 12.1 KEY COMPANIES
  • (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
    • 12.1.1 IQVIA
    • TABLE 354 IQVIA: BUSINESS OVERVIEW
    • FIGURE 54 IQVIA: COMPANY SNAPSHOT
    • TABLE 355 IQVIA: SERVICE OFFERINGS
    • TABLE 356 IQVIA: SERVICE LAUNCHES
    • TABLE 357 IQVIA: DEALS
    • TABLE 358 IQVIA: EXPANSION
    • 12.1.2 LABCORP
    • TABLE 359 LABCORP: BUSINESS OVERVIEW
    • FIGURE 55 LABCORP: COMPANY SNAPSHOT
    • TABLE 360 LABCORP: SERVICE OFFERINGS
    • TABLE 361 LABCORP: SERVICE LAUNCHES
    • TABLE 362 LABCORP: DEALS
    • TABLE 363 LABCORP: EXPANSION
    • 12.1.3 SYNEOS HEALTH INC.
    • TABLE 364 SYNEOS HEALTH INC.: BUSINESS OVERVIEW
    • FIGURE 56 SYNEOS HEALTH INC.: COMPANY SNAPSHOT
    • TABLE 365 SYNEOS HEALTH INC.: SERVICE OFFERINGS
    • TABLE 366 SYNEOS HEALTH INC: SERVICE LAUNCHES
    • TABLE 367 SYNEOS HEALTH INC.: DEALS
    • 12.1.4 WUXI APPTEC
    • TABLE 368 WUXI APPTEC: BUSINESS OVERVIEW
    • FIGURE 57 WUXI APPTEC: COMPANY SNAPSHOT
    • TABLE 369 WUXI APPTEC : SERVICE OFFERINGS
    • TABLE 370 WUXI APPTEC: SERVICE LAUNCHES
    • TABLE 371 WUXI APPTEC: DEALS
    • TABLE 372 WUXI APPTEC: EXPANSION
    • 12.1.5 CHARLES RIVER LABORATORIES
    • TABLE 373 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
    • FIGURE 58 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
    • TABLE 374 CHARLES RIVER LABORATORIES: SERVICE OFFERINGS
    • TABLE 375 CHARLES RIVER LABORATORIES: DEALS
    • TABLE 376 CHARLES RIVER LABORATORIES: EXPANSION
    • 12.1.6 PAREXEL INTERNATIONAL
    • TABLE 377 PAREXEL INTERNATIONAL: BUSINESS OVERVIEW
    • TABLE 378 PAREXEL INTERNATIONAL: SERVICE OFFERINGS
    • TABLE 379 PAREXEL INTERNATIONAL: SERVICE LAUNCHES
    • TABLE 380 PAREXEL INTERNATIONAL: DEALS
    • TABLE 381 PAREXEL INTERNATIONAL: EXPANSION
    • 12.1.7 PRA HEALTH SCIENCES
    • TABLE 382 PRA HEALTH SCIENCES: BUSINESS OVERVIEW
    • FIGURE 59 PRA HEALTH SCIENCES: COMPANY SNAPSHOT
    • TABLE 383 PRA HEALTH SCIENCES: SERVICE OFFERINGS
    • TABLE 384 PRA HEALTH SCIENCES: SERVICE LAUNCHES
    • TABLE 385 PRA HEALTH SCIENCES: DEALS
    • TABLE 386 PRA HEALTH SCIENCES: EXPANSION
    • 12.1.8 PPD INC
    • TABLE 387 PPD INC: BUSINESS OVERVIEW
    • FIGURE 60 PPD INC: COMPANY SNAPSHOT
    • TABLE 388 PPD INC: SERVICE OFFERINGS
    • TABLE 389 PPD: SERVICE LAUNCHES
    • TABLE 390 PPD: DEALS
    • TABLE 391 PPD: EXPANSION
    • 12.1.9 ICON PLC
    • TABLE 392 ICON PLC: BUSINESS OVERVIEW
    • FIGURE 61 ICON PLC: COMPANY SNAPSHOT
    • TABLE 393 ICON PLC: SERVICE OFFERINGS
    • TABLE 394 ICON PLC : SERVICE LAUNCHES
    • TABLE 395 ICON PLC: DEALS
    • 12.1.10 MEDPACE HOLDINGS INC
    • TABLE 396 MEDPACE HOLDINGS INC: BUSINESS OVERVIEW
    • FIGURE 62 MEDPACE HOLDINGS INC: COMPANY SNAPSHOT
    • TABLE 397 MEDPACE HOLDINGS INC: SERVICE OFFERINGS
    • TABLE 398 MEDPACE HOLDINGS INC: DEALS
    • TABLE 399 MEDPACE HOLDINGS INC: EXPANSION
    • 12.1.11 SGS
    • TABLE 400 SGS: BUSINESS OVERVIEW
    • FIGURE 63 SGS: COMPANY SNAPSHOT
    • TABLE 401 SGS: SERVICE OFFERINGS
    • TABLE 402 SGS: DEALS
    • 12.1.12 FRONTAGE HOLDINGS CORPORATION
    • TABLE 403 FRONTAGE HOLDINGS CORPORATION: BUSINESS OVERVIEW
    • FIGURE 64 FRONTAGE HOLDINGS CORPORATION: COMPANY SNAPSHOT
    • TABLE 404 FRONTAGE HOLDINGS CORPORATION: SERVICE OFFERINGS
    • TABLE 405 FRONTAGE HOLDINGS CORPORATION: DEALS
    • TABLE 406 FRONTAGE HOLDINGS CORPORATION: EXPANSION
    • 12.1.13 PSI CRO AG
    • TABLE 407 PSI CRO AG: BUSINESS OVERVIEW
    • TABLE 408 PSI CRO AG: SERVICE OFFERINGS
    • TABLE 409 PSI CRO AG: EXPANSION
    • 12.1.14 BIO AGILE THERAPEUTICS
    • TABLE 410 BIO AGILE THERAPEUTICS: BUSINESS OVERVIEW
    • TABLE 411 BIO AGILE THERAPEUTICS: SERVICE OFFERINGS
    • 12.1.15 FIRMA CLINICAL RESEARCH
    • TABLE 412 FIRMA CLINICAL RESEARCH: BUSINESS OVERVIEW
    • TABLE 413 FIRMA CLINICAL RESEARCH: SERVICE OFFERINGS
    • 12.1.16 ACCULAB LIFE SCIENCES
    • TABLE 414 ACCULAB LIFE SCIENCES: BUSINESS OVERVIEW
    • TABLE 415 ACCULAB LIFE SCIENCES: SERVICE OFFERINGS
    • 12.1.17 NOVOTECH HEALTH HOLDINGS
    • TABLE 416 NOVOTECH HEALTH HOLDINGS: BUSINESS OVERVIEW
    • TABLE 417 NOVOTECH HEALTH HOLDINGS: SERVICE OFFERINGS
    • TABLE 418 NOVOTECH HEALTH HOLDINGS: DEALS
    • 12.1.18 GENETICIST INC.
    • TABLE 419 GENETICIST INC.: BUSINESS OVERVIEW
    • TABLE 420 GENETICIST INC.: SERVICE OFFERINGS
    • 12.1.19 LINICAL AMERICAS
    • TABLE 421 LINICAL AMERICAS: BUSINESS OVERVIEW
    • TABLE 422 LINICAL AMERICAS: SERVICE OFFERINGS
    • TABLE 423 LINICAL AMERICAS: DEALS
    • 12.1.20 CELERION
    • TABLE 424 CELERION.: BUSINESS OVERVIEW
    • TABLE 425 CELERION.: SERVICE OFFERINGS
    • TABLE 426 CELERION.: SERVICE LAUNCHES
  • 12.2 OTHER PLAYERS
    • 12.2.1 AZELIX
    • TABLE 427 AZELIX: COMPANY OVERVIEW
    • 12.2.2 CTSERV
    • TABLE 428 CTSERV: COMPANY OVERVIEW
    • 12.2.3 PEPGRA
    • TABLE 429 PEPGRA: COMPANY OVERVIEW
    • 12.2.4 AXCENT ADVANCED ANALYTICS (A3)
    • TABLE 430 AXCENT ADVANCED ANALYTICS (A3): COMPANY OVERVIEW
    • 12.2.5 DOVE QUALITY SOLUTIONS
    • TABLE 431 DOVE QUALITY SOLUTIONS: COMPANY OVERVIEW
  • *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS